TY - JOUR
T1 - New Frontiers in Prostate Cancer Treatment
T2 - Are We Ready for Drug Combinations with Novel Agents?
AU - Aurilio, Gaetano
AU - Cimadamore, Alessia
AU - Santoni, Matteo
AU - Nolè, Franco
AU - Scarpelli, Marina
AU - Massari, Francesco
AU - Lopez-Beltran, Antonio
AU - Cheng, Liang
AU - Montironi, Rodolfo
N1 - Copyright:
This record is sourced from MEDLINE/PubMed, a database of the U.S. National Library of Medicine
PY - 2020/6/22
Y1 - 2020/6/22
N2 - Medical treatment for metastatic castration-resistant prostate cancer (mCRPC) patients has progressively been evolving from a nonspecific clinical approach to genomics-oriented therapies. The scientific community is in fact increasingly focusing on developing DNA damage repair (DDR) defect-driven novel molecules, both as single-agent therapy and in combined treatment strategies. Accordingly, research is under way into combined drug therapies targeting different pathways, e.g. androgen receptor signaling (ARS) and poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) enzymes, immune checkpoint (IC) and PARP, IC, and ARS, and prostate-specific membrane antigen (PSMA). In an attempt to formulate evolving treatment paradigms in mCRPC patients, here we selected clinical research into patients undergoing therapies with emerging molecules, with particular emphasis towards PARP-, IC-, and PSMA-inhibitors. In order to focus on those molecules and drug combinations most likely to be translated into routine clinical care in the near future, we selected only those clinical studies currently recruiting patients. A PubMed search focusing on the keywords "prostate cancer", "metastatic castration-resistant prostate cancer", "DDR pathways", "ARS inhibitors", "PARP inhibitors", "IC inhibitors", "PSMA-targeting agents", and "drug combinations" was performed.
AB - Medical treatment for metastatic castration-resistant prostate cancer (mCRPC) patients has progressively been evolving from a nonspecific clinical approach to genomics-oriented therapies. The scientific community is in fact increasingly focusing on developing DNA damage repair (DDR) defect-driven novel molecules, both as single-agent therapy and in combined treatment strategies. Accordingly, research is under way into combined drug therapies targeting different pathways, e.g. androgen receptor signaling (ARS) and poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) enzymes, immune checkpoint (IC) and PARP, IC, and ARS, and prostate-specific membrane antigen (PSMA). In an attempt to formulate evolving treatment paradigms in mCRPC patients, here we selected clinical research into patients undergoing therapies with emerging molecules, with particular emphasis towards PARP-, IC-, and PSMA-inhibitors. In order to focus on those molecules and drug combinations most likely to be translated into routine clinical care in the near future, we selected only those clinical studies currently recruiting patients. A PubMed search focusing on the keywords "prostate cancer", "metastatic castration-resistant prostate cancer", "DDR pathways", "ARS inhibitors", "PARP inhibitors", "IC inhibitors", "PSMA-targeting agents", and "drug combinations" was performed.
KW - ARS inhibitors
KW - DNA damage repair
KW - drug combinations
KW - immune checkpoint inhibitors
KW - metastatic castration-resistant prostate cancer
KW - PARP inhibitors
KW - prostate cancer
KW - PSMA-inhibition
UR - http://www.scopus.com/inward/record.url?scp=85087100351&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087100351&partnerID=8YFLogxK
U2 - 10.3390/cells9061522
DO - 10.3390/cells9061522
M3 - Review article
C2 - 32580469
AN - SCOPUS:85087100351
VL - 9
JO - Cells
JF - Cells
SN - 2073-4409
IS - 6
ER -